Bioimpacts. 2019;9(3):123-127.
doi: 10.15171/bi.2019.16
  Abstract View: 132
  PDF Download: 2


Recent advances in targeted therapy of colorectal cancer: Impacts of monoclonal antibodies nanoconjugates


Despite the rapid advances in diagnostic and treatments approaches, the overall survival rate of cancer has not been improved. Colorectal cancer (CRC) is recognized as the third leading neoplasm mortality worldwide, in large part due to its considerable metastasis and drug resistance. For developing new anticancer strategies, rapid progression of multimodal nanomedicines and nanoconjugates has provided promising treatment modalities for effective therapy of cancer. The limitations of cancer chemotherapy might be overcome through the use of such nanosized therapeutics, including nanoconjugates of monoclonal antibodies (mAbs) with drugs and organic/inorganic nanoparticles (NPs). CRC cells express various molecular markers against which mAbs can be designed and used as targeting/therapeutic agents. This editorial highlights the importance of such targeted nanosystems (NSs) against CRC.
First name
Last name
Email address
Security code

Article Viewed: 132

Your browser does not support the canvas element.

PDF Downloaded: 2

Your browser does not support the canvas element.

Submitted: 10 Nov 2018
Revised: 26 Nov 2018
Accepted: 26 Nov 2018
First published online: 08 Mar 2019
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)